SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending following strong earnings that surpassed expectations, driven by significant year-over-year revenue growth and an optimistic 2026 guidance, which has prompted analyst upgrades. The community is actively discussing its high valuation amidst accelerating U.S. commercial and AI platform adoption, with bulls celebrating its "blowout results" while bears question the sustainability of its growth.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending as investors await its upcoming earnings report, with community sentiment sharply divided between those predicting further declines, influenced by recent analyst downgrades, and others asserting its deep value and oversold conditions could trigger a significant rebound amid widespread beliefs of market manipulation.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is trending following a JPMorgan upgrade to Overweight, igniting community debate over its perceived oversold status and the potential for a short squeeze. Despite reporting strong earnings and ongoing speculation about S&P 500 inclusion, many investors are expressing frustration with the stock's recent performance.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as the community eagerly anticipates robust Q4 earnings, driven by the significant easing of competitive price wars with rivals and sustained rapid global store expansion. Despite its strong growth and perceived undervaluation compared to competitors, investors are frustrated by its continued OTC status and actively call for a major exchange uplisting to unlock its full market potential.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending intensely ahead of its earnings report, driven by community expectations for a substantial revenue beat and a potential short squeeze, with optimism amplified by its critical role in AI infrastructure, particularly for Elon Musk's xAI after its merger with SpaceX, amidst ongoing debates over valuation and management's past performance.

Rambus, Inc. engages in the provision of cutting-edge semiconductor and Internet Protocol products, spanning memory and interfaces to security, smart sensors and lighting. Its products include Memory Interface Chips, Interface IP, and Security IP. The company was founded by P. Michael Farmwald and Mark A. Horowitz in March 1990 and is headquartered in Sunnyvale, CA.

Rambus Inc.

Following its Q4 2025 earnings and Q1 2026 revenue guidance that missed analyst estimates, Rambus experienced a significant sell-off, sparking community debate over whether the sharp decline is an overreaction to a temporary operational issue or a justified correction within the high-demand memory and AI sector.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

Wave Life Sciences is generating significant buzz after early clinical data showed its obesity candidate, WVE-007, achieved fat loss while preserving muscle mass and demonstrated favorable tolerability, differentiating it from current GLP-1 therapies. While analysts raise price targets on its "paradigm-shifting" potential and major pharma's hunt for next-generation treatments, investors are weighing this against the early phase data and dilution from a recent public offering.

Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce. Its platform consists of three core elements: a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The company was founded by Max R. Levchin in 2012 and is headquartered in San Francisco, CA.

Affirm Holdings Inc - Ordinary Shares - Class A

Affirm Holdings Inc

Affirm is trending amid recent analyst upgrades and expanded partnerships with Amazon and Expedia, which are battling a critical short report and market uncertainty over proposed credit card rate caps. The community is actively discussing strong fundamentals versus claims of manipulation ahead of the upcoming earnings report, highlighting the polarized outlook on the Buy Now, Pay Later sector.

Corning, Inc. engages in the provision of glass for notebook computers, flat panel desktop monitors, display televisions, and other information display applications, carrier network and enterprise network products for the telecommunications industry, ceramic substrates for gasoline and diesel engines in automotive and heavy-duty vehicle markets, laboratory products for the scientific community and polymer products for biotechnology applications, optical materials for the semiconductor industry and the scientific community, and polycrystalline silicon products and other technologies. It operates through the following segments: Optical Communications, Display Technologies, Specialty Materials, Environmental Technologies, and Life Sciences. The Optical Communications segment is classified into two main product groupings: carrier and enterprise network. The carrier network group consists of products and solutions for optical-based communications infrastructure for services such as video, data, and voice communications. The enterprise network group consists primarily of optical-based communication networks sold to businesses, governments, and individuals for their own use. The Display Technologies segment manufactures glass substrates for flat panel displays, including organic light-emitting diodes and liquid crystal displays that are used primarily in televisions, notebook computer, desktop monitors, tablets, and handheld devices. The Specialty Materials segment is involved in the manufacture of products that provide material formulations for glass, glass ceramics and crystals, and precision metrology instruments and software. The Environmental Technologies segment focuses on manufacturing ceramic substrates and filter products for emissions control in mobile applications. The Life Sciences segment develops, manufactures, and supplies laboratory products. The company was founded by Amory Houghton Sr. in 1851 and is headquartered in Corning, NY.

Corning, Inc.

Corning is trending as its significant multi-year agreement to supply optical fiber for a major tech company's AI data centers is seen by the community as a transformative validation of its critical infrastructure role. Community sentiment is highly bullish, anticipating further hyperscaler contracts and highlighting its proprietary fiber technology and essential role in glass for leading consumer electronics, cementing its position as a key infrastructure play in the AI and digital landscape.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is trending as investors await its crucial earnings report, eager for management to emphasize the significant expansion of its Helios AI data center capacity and its strengthened CoreWeave partnership, which are expected to de-risk its business amid ongoing cryptocurrency market volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Federated Hermes Inc. Makes New Investment in Genmab A/S Sponsored ADR $GMAB

Federated Hermes Inc. bought a new position in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and...

$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium

$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium PR Newswire VANCOUVER, BC, Jan...

What is HC Wainwright's Estimate for Genmab A/S Q4 Earnings?

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) - Equities research analysts at HC Wainwright upped their Q4 2025 earnings per share estimates for shares of Genmab A/S in a research report...

Genmab A/S (NASDAQ:GMAB) Shares Gap Down - Here's What Happened

Genmab A/S (NASDAQ:GMAB) Shares Gap Down - What's Next...

Genmab A/S (NASDAQ:GMAB) Price Target Lowered to $39.00 at HC Wainwright

HC Wainwright reduced their price target on Genmab A/S from $41.00 to $39.00 and set a "buy" rating for the company in a research report on Tuesday...

<ul class="summary-bullets"><li>While the study also showed an improvement in other key aspects such as complete response rates and duration of response, it did not demonstrate a statistically significant improvement in overall survival.&nbsp;</li><li>Diffuse Large B-Cell Lymphoma (DLBCL) is the most common and aggressive type of non-Hodgkin lymphoma.</li><li>The company said it now intends to engage with regulatory authorities to discuss the next steps for the drug together with its partner AbbVie.</li></ul> Genmab A/S (GMAB) said on Friday that its late-stage trial evaluating drug Epcoritamab demonstrated an improvement in progression-free survival in certain patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma.While the study also showed an improvement in other key aspects such as complete response rates and duration of response, it did not demonstrate a statistically significant improvement in overall survival, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/16/3220513/0/en/Genmab-Announces-Topline-Results-for-Epcoritamab-DuoBody-CD3xCD20-from-Phase-3-EPCORE-DLBCL-1-Trial-in-Patients-with-Relapsed-Refractory-Diffuse-Large-B-cell-Lymphoma-DLBCL.html">said.</a> While progression-free survival represents the time a patient lives with cancer without it getting worse or dying, overall survival is the length of time from diagnosis or treatment start until death from any cause.<h2 class="st-heading-2">Study Details</h2>Genmab enrolled 483 patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma in the trial who had undergone at least one prior line of therapy. These patients were ineligible for high-dose chemotherapy, the company said.Diffuse Large B-Cell Lymphoma (DLBCL) is the most common and aggressive type of non-Hodgkin lymphoma, a blood cancer involving rapid growth of large B-lymphocytes in the lymphatic system, lymph nodes, and other organs, often presenting as fast-growing masses or swollen nodes with symptoms like fever, night sweats, and weight loss. According to Genmab, there are approximately 25,000 new cases of DLBCL diagnosed each year in the U.S.The company said it intends to now engage with regulatory authorities to discuss the next steps for the drug together with its partner AbbVie. Epcoritamab, being co-developed by Genmab and AbbVie, is already approved in several countries for the treatment of certain lymphomas.Shares of GMAB fell 5% at the time of writing.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around GMAB stock stayed within the ‘bearish’ territory coupled with ‘high’ message volume.Meanwhile, sentiment around ABBV shares rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.A Stocktwits user sees GMAB stock plummet down to $20 from current levels.<stembedurl>https://www.stocktwits.com/nopumpdump/message/642093162</stembedurl><a href="https://stocktwits.com/symbol/GMAB">GMAB stock</a> has gained 51% over the past 12 months while <a href="https://stocktwits.com/symbol/ABBV">ABBV shares</a> added 24%.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nvo-shares-rise-on-strong-kickstart-for-wegoy-pill-in-us/cmUlCCgR4Bq">NVO Shares Rise On Strong Kickstart For Wegovy Pill In US: Retail Eyes Up To $110 As ‘Fair Value’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Genmab logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Genmab Stock Drops On Mixed Results From Late-Stage Trial Of Lymphoma Drug

Epcoritamab demonstrated an improvement in progression-free survival in certain patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma, the company said.

Equity

Epcoritamab demonstrated an improvement in progression-free survival in certain patients with relapsed or refractory diffuse large B-cell lymphoma, the company said.


Genmab Announces Topline Results for Epcoritamab (DuoBody CD3xCD20) from Phase 3 EPCORE DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, which...

Genmab A/S (OTCMKTS:GNMSF) Shares Gap Down - What's Next?

Genmab A/S (OTCMKTS:GNMSF) Shares Gap Down - Should You Sell...

Genmab A/S (NASDAQ:GMAB) Hits New 52-Week High - Time to Buy?

Genmab A/S (NASDAQ:GMAB) Hits New 12-Month High - Here's What Happened...

Genmab A/S (OTCMKTS:GNMSF) Shares Gap Up - Here's Why

Genmab A/S (OTCMKTS:GNMSF) Shares Gap Up - Should You Buy...

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Genmab - ADR

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $AMD earnings on Tuesday?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.44	--	--	N/A
Q3 '25	$0.49	$0.65	32.89%	BEAT
Q2 '25	$0.40	$0.54	35.74%	BEAT
Q1 '25	$0.24	$0.31	25.34%	BEAT
Q4 '24	$0.44	--	--	N/A

GMAB
Genmab - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest GMAB News

GMABGenmab - ADR